Modeling international cooperation under the WHO Pandemic Accord — pathogen data sharing, vaccine equity, and compliance versus sovereign go-it-alone response
Before any binding international framework, pandemic response is a patchwork of 194 sovereign decisions. Pathogen samples, genomic sequence data, and vaccine doses are treated as national assets rather than shared global goods. The result, repeatedly, is slower outbreak detection, redundant vaccine races among wealthy blocs, and near-total exclusion of lower-income countries from early countermeasures.
Pandemic preparedness is a textbook global public good: no single nation captures the full benefit of its own investment in surveillance, and no nation can wall itself off from a pathogen that ignores borders. Left purely to sovereign incentive, each government under-invests relative to the collective optimum — genomic surveillance networks are patchy, sample-sharing is discretionary, and vaccine manufacturing capacity clusters in a handful of wealthy states.
The 2007 Indonesia dispute crystallized the problem: Jakarta stopped sharing H5N1 avian-flu samples with WHO's Global Influenza Surveillance and Response System (GISRS), arguing it was unacceptable for wealthy countries to receive vaccines derived from Indonesian viral samples while Indonesia itself had no guaranteed access to the resulting product. The standoff was not resolved by goodwill — it produced the 2011 Pandemic Influenza Preparedness (PIP) Framework, the direct institutional ancestor of the mechanisms modeled in later stages here.
COVAX, the COVID-19 vaccine-sharing facility launched in 2020, was designed explicitly to prevent the sovereign-hoarding pattern — and largely failed to do so in its first eighteen months. High-income countries, representing roughly 16% of world population, pre-purchased more than half of the earliest confirmed vaccine doses through direct bilateral deals with manufacturers, leaving COVAX chronically under-supplied. By September 2021, under 5% of people in low-income countries had received even a single dose, against 50%+ in high-income countries.
This asymmetry was not simply a manufacturing bottleneck — it was a demonstration that voluntary, non-binding pooling mechanisms collapse under the pressure of domestic political incentives during an actual crisis. That lesson is what pushed WHO member states toward negotiating a binding instrument rather than relying on ad hoc facilities built after the fact.
The core diagnosis behind the Pandemic Accord: COVAX was a charity model bolted onto a system of sovereign vaccine nationalism. The treaty instead tries to build equity obligations into the manufacturing and data-sharing pipeline itself, before the next crisis begins.
Formal negotiations opened in December 2021 when the World Health Assembly established the Intergovernmental Negotiating Body (INB), tasked with drafting a convention, agreement, or other international instrument under the WHO Constitution to strengthen pandemic prevention, preparedness, and response. More than three years of drafting, walkouts, and last-minute compromise followed before adoption.
Two issues dominated and repeatedly stalled the talks. First, the Pathogen Access and Benefit-Sharing (PABS) mechanism — how to guarantee that countries sharing pathogen samples and genomic sequence data receive a share of the resulting diagnostics, therapeutics, and vaccines — proved so contentious that its operational annex was left for a follow-up negotiation even after the main treaty text was adopted. Low- and middle-income countries, remembering COVAX, wanted binding guarantees; a bloc of vaccine-manufacturing states resisted language that could be read as compelling technology transfer or intellectual-property waivers.
Second, sovereignty language: several delegations insisted on explicit text affirming that the treaty creates no authority for WHO to mandate lockdowns, border closures, or vaccine mandates within any state — a direct response to misinformation campaigns that framed the accord as ceding national sovereignty to an international body.
Adoption by the World Health Assembly is a political milestone, not a legal one. Each of the 194 member states must independently ratify the agreement through its own domestic legal process — a step that in many countries requires parliamentary approval and can take years. The treaty only enters into force once 60 states complete ratification, and even then it binds only the states that have ratified.
This creates the core dynamic modeled in this stage: a widening gap between the number of states that supported adoption by consensus and the much smaller number that have completed the harder step of binding themselves domestically. Nations with the least to lose from committing (strong existing public-health institutions, no active manufacturing-capacity concerns) tend to ratify earliest; states with major pharmaceutical export industries or unresolved PABS concerns tend to ratify last, if at all.
The Pathogen Access and Benefit-Sharing (PABS) system is the treaty's attempt to generalize a narrow 2011 precedent — the Pandemic Influenza Preparedness Framework, which applied only to influenza viruses with pandemic potential — into a standing mechanism covering any pathogen. Once active, participating laboratories upload genomic sequence data to WHO-linked repositories in near real time, in exchange for guaranteed downstream access to resulting countermeasures.
PABS operates on a reciprocity logic: a state that detects a novel pathogen with pandemic potential shares genomic sequence data and physical samples through WHO-coordinated channels, and in exchange gains a standing claim on a defined share of any vaccines, therapeutics, or diagnostics subsequently developed using that material. Manufacturers benefiting from PABS-supplied biological material commit contractually to the equity provisions activated in Stage 4.
The mechanism deliberately mirrors the PIP Framework's structure — legally binding contributor agreements, a defined benefit-sharing percentage, real-time data flow through the Global Influenza Surveillance and Response System's successor infrastructure — but extends the scope from influenza alone to coronaviruses, filoviruses, and any pathogen family a WHO-declared Public Health Emergency of International Concern (PHEIC) might involve.
Genomic sequence data is the fastest, cheapest signal a health system can share — far faster than shipping physical samples, and far more useful to vaccine and diagnostic developers than delayed case-count reports. The treaty treats sequence-sharing latency as a proxy for overall system trust: a state confident it will receive fair downstream access shares data within days; a state worried about being exploited (as Indonesia was in 2007) delays or withholds it.
Modeled data-sharing compliance in this stage therefore tracks both the compliance-incentive slider and the accumulating ratification count — each additional ratifying state with functioning genomic infrastructure strengthens the shared surveillance graph, while the still-unresolved PABS annex leaves the largest manufacturing states as the network's most uncertain nodes.
The treaty's signature equity provision requires manufacturers benefiting from PABS-supplied pathogen material to set aside 20% of their real-time production of pandemic-relevant vaccines, therapeutics, and diagnostics for WHO-coordinated allocation — 10% as an outright donation and 10% at not-for-profit or affordable prices — explicitly designed to prevent a repeat of the COVAX-era doses-hoarding pattern.
COVAX relied on advance-purchase pledges that manufacturers and wealthy governments could — and did — deprioritize once bilateral deals offered faster payment and less allocation uncertainty. The 20% set-aside instead attaches directly to the legal right to use PABS-supplied biological material: a manufacturer that benefits from shared pathogen samples or sequence data is contractually bound to the set-aside as a condition of that access, not as a separate charitable commitment negotiated after the product already exists.
This timing matters enormously. Under COVAX, equity allocations competed with fully-funded bilateral orders for the same production slots, and consistently lost. Under the set-aside model, the 20% is claimed against the same real-time production run as every other order — WHO-coordinated distribution is a first-in-line contractual obligation, not a leftover.
The set-aside solves allocation priority, but not every bottleneck. Manufacturing capacity itself remains concentrated: as of the mid-2020s, a small number of countries host the overwhelming majority of global vaccine-fill-finish capacity, meaning a 20% set-aside of a small total production run still delivers a small absolute number of doses in the earliest, most valuable weeks of an outbreak. Regional manufacturing hubs (mRNA technology-transfer programs in Africa and Latin America) are a partial, still-maturing response to this constraint.
The equity index tracked in this simulator therefore rises with both the compliance-incentive slider and the equity set-aside slider, but is capped below 1.0 even under maximal settings — reflecting that legal entitlement to a share of production is necessary but not sufficient without underlying manufacturing capacity distributed across more of the 194 member states.
A 20% set-aside of a global vaccine run within the first 100 days of a declared pandemic is estimated, under treaty projections, to be an order of magnitude larger than the doses low-income countries actually received in the first 100 days of the COVID-19 rollout — the mechanism targets the timing failure, not just the total-volume failure, of the COVAX era.
The treaty's enforcement architecture is deliberately soft: a Conference of the Parties, periodic Universal Health & Preparedness Reviews, and National Focal Points for reporting — but no sanctions mechanism, trade penalties, or judicial enforcement body. Compliance rests on transparency, peer pressure, and the accumulated self-interest of staying inside a functioning cooperation network. This final stage compares simulated outbreak trajectories under full treaty cooperation against the Stage 1 sovereign-nations baseline.
Binding international law with real sanctions (trade penalties, judicial recourse) was politically unreachable in these negotiations — several major states would not ratify a treaty that exposed them to external enforcement over domestic public-health decisions. The compromise is a "soft law within a hard commitment" design: the underlying obligations (data-sharing, set-asides, reporting) are legally binding on ratifying states, but the mechanism for ensuring compliance is reputational rather than punitive.
The Universal Health & Preparedness Review functions like a peer-review process: member states report on their own preparedness and compliance, and other states and independent experts scrutinize those reports publicly. The theory of change is that no state wants to be publicly identified as the weak link in a system its neighbors depend on — particularly once enough states have ratified that non-compliance becomes reputationally costly rather than politically convenient.
In the no-treaty baseline (Stage 1), an emerging pathogen spreads through the nation-network with no shared surveillance graph: detection in one country does not accelerate detection or response anywhere else, sequence data stays local for weeks, and vaccine development races proceed independently in whichever countries have manufacturing capacity — producing a modeled response time upward of 180 days from emergence to broad-based countermeasure availability.
Under full treaty cooperation, the same emergence event propagates through an active data-sharing and vaccine-flow network: genomic sequence data reaches WHO-linked repositories within days (Stage 3 mechanism), manufacturing begins against a shared target faster, and the 20% set-aside (Stage 4 mechanism) distributes early doses across ratifying states rather than concentrating them in the country of origin — compressing modeled response time toward the 30–40 day range in the highest-compliance settings.
The gap between these two trajectories is not primarily a biology or manufacturing-technology story — both scenarios assume identical scientific capability. The entire difference is coordination: how quickly information and countermeasures cross the same 194 borders that, in the baseline scenario, act as barriers rather than nodes in a network.